Market research
PDPL.NSE Parenteral Drugs (India) Limited
NSE INR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 101M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.16
Community
Investor discussion
1 comment
Sign in to join the PDPL.NSE discussion.
5 years, 5 months ago
Parenteral Drugs (India) Limited is currently in a long term uptrend where the price is trading 40.8% above its 200 day moving average.
From a valuation standpoint, the stock is 81.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Parenteral Drugs (India) Limited's total revenue sank by 71.9% to $20M since the same quarter in the previous year.
Its net income has dropped by 18.5% to $-310M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.4% to $608M since the same quarter in the previous year.
Based on the above factors, Parenteral Drugs (India) Limited gets an overall score of 3/5.